Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions

被引：197

作者：

Hato, Tai ^{[1
]}

Goyal, Lipika ^{[2
]}

Greten, Tim F. ^{[3
]}

Duda, Dan G. ^{[1
]}

Zhu, Andrew X. ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA

[3] NCI, Gastrointestinal Malignancy Sect, Thorac & Gastrointestinal Oncol Branch, Bethesda, MD 20892 USA

来源：

HEPATOLOGY | 2014年 / 60卷 / 05期

基金：

美国国家卫生研究院;

关键词：

REGULATORY T-CELLS; PERCUTANEOUS ETHANOL INJECTION; SUPPRESSOR-CELLS; POSTOPERATIVE RECURRENCE; CTLA-4; BLOCKADE; LIVER; RESPONSES; PD-1; MOLECULES; HEPATITIS;

D O I：

10.1002/hep.27246

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

引用

页码：1776 / 1782

页数：7

共 50 条

[21] Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma? [J].

Fan Zhongqi ;

Sun Xiaodong ;

Chen Yuguo ;

Lv Guoyue .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (02) :222-228

[22] Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma [J].

Yavuz, Betul Gok ;

Hasanov, Elshad ;

Lee, Sunyoung S. ;

Mohamed, Yehia, I ;

Curran, Michael A. ;

Koay, Eugene J. ;

Cristini, Vittorio ;

Kaseb, Ahmed O. .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 :1195-1207

[23] Immune checkpoint inhibitor resistance in hepatocellular carcinoma [J].

Wang, Zhijie ;

Wang, Yichuan ;

Gao, Peng ;

Ding, Jin .

CANCER LETTERS, 2023, 555

[24] Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions [J].

Haddad, Alexander F. ;

Young, Jacob S. ;

Gill, Sabraj ;

Aghi, Manish K. .

SEMINARS IN CANCER BIOLOGY, 2022, 86 :532-541

[25] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives [J].

Federico, Piera ;

Petrillo, Angelica ;

Giordano, Pasqualina ;

Bosso, Davide ;

Fabbrocini, Antonietta ;

Ottaviano, Margaret ;

Rosanova, Mario ;

Silvestri, Antonia ;

Tufo, Andrea ;

Cozzolino, Antonio ;

Daniele, Bruno .

CANCERS, 2020, 12 (10) :1-20

[26] Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors [J].

Zhu, Yingming ;

Zhao, Fen ;

Li, Zhenxiang ;

Yu, Jinming .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :2475-2488

[27] The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma [J].

Kou, Liqiu ;

Xie, Xiaolu ;

Chen, Xiu ;

Li, Bo ;

Li, Jun ;

Li, Yaling .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (12) :3953-3969

[28] Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade [J].

Lei, Yanna ;

Li, Xiaoying ;

Huang, Qian ;

Zheng, Xiufeng ;

Liu, Ming .

FRONTIERS IN ONCOLOGY, 2021, 11

[29] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma [J].

Machairas, Nikolaos ;

Tsilimigras, Diamantis, I ;

Pawlik, Timothy M. .

CANCERS, 2022, 14 (08)

[30] Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology [J].

Barbee, Meagan S. ;

Ogunniyi, Adebayo ;

Horvat, Troy Z. ;

Dang, Thu-Oanh .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (08) :907-937

← 1 2 3 4 5 →